S&P Futures
4,293.75 -4.50 (-0.10%) Dow Futures
33,870.00 -3.00 (-0.01%) Nasdaq Futures
13,667.25 -14.00 (-0.10%) Russell 2000 Futures
2,022.80 -1.00 (-0.05%) Crude Oil
88.84 -0.57 (-0.64%) Gold
1,796.10 -2.00 (-0.11%)
DSS, Inc. (DSS)
After hours:
- GlobeNewswire
Impact BioMedical Develops Quantum Antihistamine
ROCHESTER, N.Y., July 26, 2022 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company operating businesses within nine divisions and strategically acquiring and developing assets to enrich the value of its shareholders through calculated IPO spinoffs and a parametric share distribution strategy, today announced that less than a year after successfully synthesizing its first Quantum-based compound, Impact Biomedical, Inc. and its research partner Global Research and Discovery
- GlobeNewswire
DSS Announces Licensing of Impact BioMedical’s Linebacker Portfolio to ProPhase Labs
ROCHESTER, N.Y., July 21, 2022 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company operating businesses within nine divisions and strategically acquiring and developing assets to enrich the value of its shareholders through calculated IPO spinoffs and a parametric share distribution strategy, today announced Global BioLife, Inc. (“Global BioLife”), a subsidiary of the Company’s wholly owned subsidiary Impact BioMedical, Inc. (“Impact BioMedical”), executed a license agree
- GlobeNewswire
DSS Strengthens and Expands Board with Appointment of Two Independent Directors
ROCHESTER, N.Y., July 13, 2022 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company operating businesses within nine divisions and strategically acquiring and developing assets to enrich the value of its shareholders through calculated IPO spinoffs and a parametric share distribution strategy, today announced the expansion of its Board of Directors with the appointment of two independent directors, Frankie Wong, a 20-year veteran of public-company financial reporting, and
